title: Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy.
abstract: Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.
authors.affiliation: Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.
authors.forename: Stephen I
authors.initials: SI
authors.lastname: Pelton
authors.forename: Ron
authors.initials: R
authors.lastname: Dagan
authors.forename: Beverly M
authors.initials: BM
authors.lastname: Gaines
authors.forename: Keith P
authors.initials: KP
authors.lastname: Klugman
authors.forename: Dagna
authors.initials: D
authors.lastname: Laufer
authors.forename: Katherine
authors.initials: K
authors.lastname: O'Brien
authors.forename: Heinz J
authors.initials: HJ
authors.lastname: Schmitt
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005544:Forecasting; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D022242:Pneumococcal Vaccines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000382:microbiology* / Q000517:prevention & control*; D011358:Product Surveillance, Postmarketing / Q000639:trends; D013296:Streptococcus pneumoniae / Q000254:growth & development / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate